Kroger Surges 8% on CEO News; Shipping Hikes Loom 02/09/26
/
RSS Feed
Kroger Surges 8% on CEO News; Shipping Hikes Loom 02/09/26
Key Stories:
- Shares of Kroger, the prominent U.S. grocer, saw a significant boost Monday morning, climbing more than 8%. This surge came after the company announced the appointment of Greg Foran, a highly regarded former Walmart executive, as its new CEO. Foran is credited with successfully turning around Walmart’s U.S. business, managing over 4,600 stores, and significantly enhancing its digital presence through online ordering and pickup initiatives. This leadership change follows a year-long search and the departure of the former CEO. Analysts from Morgan Stanley suggest Foran’s immediate focus at Kroger will likely be on strengthening in-store execution and accelerating online growth, especially as the grocer navigates persistent inflation impacting consumer spending. Investors will be closely watching his strategic moves to see if he can replicate his past successes. Read more
- While some companies navigate internal changes, a broader economic pressure point is emerging for e-commerce. Major carriers like UPS and FedEx are rolling out their 2026 rate structures, which are set to significantly squeeze online retailers’ margins. Although the headline General Rate Increases, or GRIs, are quoted at 5.9%, the effective increases are expected to hit a much steeper 10% to 20% once various surcharges are factored in. This trend means shipping costs are no longer just an operational expense; they’re evolving into a core component of the Cost of Goods Sold, or COGS, for online businesses. This shift will force e-commerce platforms to re-evaluate their pricing strategies and operational efficiencies, potentially impacting consumer prices and the overall profitability of the sector. Read more
- Shifting gears to the pharmaceutical sector, Guggenheim recently increased its price target for Bristol-Myers Squibb Company, or BMY, to $72, up from its previous $62, while reiterating a Buy rating on the stock. This positive analyst sentiment stems from a significant increase in the estimated probability of success for BMY’s experimental drug, iber/mezi, which Guggenheim now pegs at 90%, a substantial jump from the prior 33%. Bristol-Myers Squibb is often highlighted as one of the more profitable undervalued stocks to consider, and this revised outlook on its pipeline success could signal strong growth potential for the company and its investors, making it a key stock to watch in the healthcare space. Read more
Keywords: Analyst upgrade, BMY, Biotech, Buy rating, CEO, COGS, Drug pipeline, E-commerce, FedEx, Grocer, Guggenheim, Inflation, Inflationary pressure, KR, Leadership change, Logistics, Margins, Pharmaceutical, Price target, Retail, Shipping rates, Stock surge, UPS, Walmart